Cabaletta Bio closed at $1.42 on Nov 4, unchanged, 65.8% below its 52-week closing high. Volume of 3.2M shares was 0.65× its 20-day average (below normal).
Split-adjusted performance: -29.7% over one month, -61.9% over six months, -52.8% over one year.
Short interest was 39.3M shares at the Oct 15 settlement, up 1.7% from the prior report (27.4% of float, 7.2 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CABACabaletta Bio | $1.42 | 0.00% | −61.9% | — | — | — | $240.8M | |
| PROKProKidney | $1.12 | +4.67% | −42.9% | −32.1% | −18948.0% | — | $234.1M | Compare |
| FATEFate Therapeutics | $2.09 | +2.45% | −8.7% | +9.2% | −1448.6% | — | $250.4M | Compare |
| ALECAlector | $2.28 | +11.22% | −11.3% | −57.8% | −692.5% | — | $254.6M | Compare |
| DTILPrecision BioSciences | $8.12 | +16.50% | +8.0% | −100.0% | — | — | $224.1M | Compare |
| LCTXLineage Cell Therapeutics | $1.03 | +1.98% | −28.0% | −61.3% | 138.6% | — | $260.5M | Compare |
| LXEOLexeo Therapeutics | $3.23 | +3.86% | −48.2% | — | — | — | $265.1M | Compare |
| IKTInhibikase Therapeutics | $1.57 | +5.74% | −22.1% | — | — | — | $218.4M | Compare |
| PALIPalisade Bio | $1.25 | +1.63% | −37.5% | — | −2114.8% | — | $217.8M | Compare |
No recent articles focused on Cabaletta Bio. 1 articles mention it in passing.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
